

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6781712

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	ADIMAB, LLC	06/21/2021
RECEIVING PARTY DATA		
Name:	ADAGIO THERAPEUTICS, INC.	
Street Address:	7303 WYMAN STREET	
Internal Address:	SUITE 300	
City:	WALTHAM	
State/Country:	MASSACHUSETTS	
Postal Code:	02451	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	17226153
CORRESPONDENCE DATA		
Fax Number:	(617)607-9200	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	6174496500	
Email:	lmargolis@mccarter.com	
Correspondent Name:	MCCARTER & ENGLISH, LLP	
Address Line 1:	265 FRANKLIN STREET	
Address Line 4:	BOSTON, MASSACHUSETTS 02110	
ATTORNEY DOCKET NUMBER:	132280-00113	
NAME OF SUBMITTER:	MARCIE B. CLARKE, PH.D., ESQ.	
SIGNATURE:	/Marcie B. Clarke/	
DATE SIGNED:	06/25/2021	
Total Attachments: 4		
source=132280_00113 Assignment (Adimab to Adagio FULLY EXECUTED)#page1.tif		
source=132280_00113 Assignment (Adimab to Adagio FULLY EXECUTED)#page2.tif		
source=132280_00113 Assignment (Adimab to Adagio FULLY EXECUTED)#page3.tif		
source=132280_00113 Assignment (Adimab to Adagio FULLY EXECUTED)#page4.tif		

ASSIGNMENT

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Adimab, LLC, having its principal place of business at 7 Lucent Drive, Lebanon, New Hampshire 03766, United States of America (hereinafter referred to as "ASSIGNOR") has sold, assigned, and transferred, and by these presents hereby sells, assigns, and transfers, unto

Adagio Therapeutics, Inc.
7303 Wyman Street
Suite 300
Waltham, Massachusetts 02451
United States of America

(hereinafter referred to as "ASSIGNEE") its successors and assigns, the full and exclusive right, title and interest for the United States, its territories and possessions, and all foreign countries in and to this invention relating to

COMPOUNDS SPECIFIC TO CORONAVIRUS S PROTEIN AND USES THEREOF

as set forth in the following Patent Application:

United States Patent Application No. 17/226,153 filed April 9, 2021

including (a) all other applications for Letters Patent of the United States and countries foreign thereto for above-identified invention or inventions, (b) all Letters Patent which may issue from said applications in the United States and countries foreign thereto, (c) all divisions, continuations, reissues, and extensions of said applications and Letters Patent, and (d) the right to claim for any of said applications the full benefits and priority rights under the International Convention and any other international agreement to which the United States adheres; such right, title, and interest to be held and enjoyed by ASSIGNEE, its successors and assigns, to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment not been made.

ASSIGNOR HEREBY AUTHORIZES ASSIGNEE to file patent applications in any or all countries on the above-identified invention or inventions in the name of the undersigned or in the name of ASSIGNEE or otherwise as ASSIGNEE may deem advisable under the International Convention or otherwise.

ASSIGNOR HEREBY AUTHORIZES AND REQUESTS the Commissioner of Patents and Trademarks to issue said Letters Patent to ASSIGNEE as assignee of the entire interest, for the sole use and benefit of ASSIGNEE, its successors and assigns.


ASSIGNOR HEREBY AGREES (a) to communicate to ASSIGNEE, its successors and assigns, or their representative or agents, all facts and information known or available to ASSIGNOR respecting said invention or inventions, including evidence for interference, reexamination, reissue, opposition, revocation, extension, or infringement purposes or other legal, judicial, or administrative proceedings, whenever requested by ASSIGNEE; (b) to testify in person or by affidavit as required by ASSIGNEE, its successors and assigns, in any such proceeding in the United States or a country foreign thereto; (c) to execute and deliver, upon request by ASSIGNEE, all lawful papers including, but not limited to, original, divisional, continuation, and reissue applications, renewals, assignments, powers of attorney, oaths, affidavits, and declarations, depositions; and (d) to provide all reasonable assistance to ASSIGNEE, its successors and assigns, in obtaining and enforcing proper title in and protection for said invention or inventions under the intellectual property laws of the United States and countries foreign thereto.

ASSIGNOR HEREBY REPRESENTS AND WARRANTS that ASSIGNOR has the full and unencumbered right to sell, assign, and transfer the interests sold, assigned, and transferred herein, and that ASSIGNOR has not executed and will not execute any document or instrument in conflict herewith.

ASSIGNOR HEREBY GRANTS to the law firm of **McCarter & English, LLP** the power and authority to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

ASSIGNOR:

Executed this 21 day of June, 2021.



Adimab, LLC

Name: ERIC KRAULAND

Title: CHIEF SCIENTIFIC OFFICER

ACKNOWLEDGEMENT:


On this 21 day of June, 2021, Eric Krauland,
personally appeared before me, executed the foregoing Assignment, and duly acknowledged to
me that such Assignment was executed by his/her free act and deed for the uses and purposes
therein expressed.


Witness signature

Amy K Bray
Witness name (please print)

Acceptance of Assignment by the Assignee:

Executed this 23 day of June, 2021.

DocuSigned by:

545E9431874C48F...

Adagio Therapeutics, Inc.

Name: Halley Gilbert

Title: COO